Entering text into the input field will update the search result below

AVIR Atea Pharmaceuticals, Inc.
Stock Price & Overview

$3.04-0.11 (-3.49%)4:00 PM 09/26/23
NASDAQ | $USD | Post-Market: $3.11 +0.07 (+2.30%) 5:36 PM


Div Rate (TTM)
Yield (TTM)
Short Interest
Market Cap
Prev. Close

Quant Ranking

Ratings Summary

Now6M ago
SA Analysts
Not CoveredRating: Not Covered
Wall Street
Not CoveredRating: Not Covered
Not CoveredRating: Not Covered

Ratings Summary

SA Analysts
Wall Street
Now3M ago6M ago
-Rating: Not Covered
-Rating: Not Covered
-Rating: Not Covered
-Rating: Not Covered
-Rating: Not Covered

See AVIR ratings with Premium.

Company Profile

Atea Pharmaceuticals, Inc. logo
Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focused on discovering, developing, and commercializing antiviral therapeutics for patients suffering from viral infections. Its lead product candidate is AT-527, an oral antiviral candidate that is in Phase III SUNRISE-3 clinical trial for the treatment of patients with COVID-19. The company also develops AT-752, a drug that is in Phase II clinical trial for the treatment and prophylaxis of dengue; and AT-281, a pharmaceutically acceptable salt for the treatment or prevention of an RNA viral infection, including dengue fever, yellow fever, and Zika virus, as well as Ruzasvir, an investigational NS5A inhibitor for the treatment of chronic HCV infection. It also develops a co-formulated, oral, pan-genotypic fixed dose combination of bemnifosbuvir and ruzasvir for the treatment of hepatitis C virous (HCV); It has a license agreement with Merck & Co, Inc. development, manufacture, and commercialization of ruzasvir for the treatment of HCV. Atea Pharmaceuticals, Inc. was incorporated in 2012 and is headquartered in Boston, Massachusetts.
  • 225 Franklin Street
  • Suite 2100
  • Boston, MA, 02110
  • United States
Phone Number
857 284 8891
To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.